Wright JD, Huang Y, Melamed A, et al. - Analyzing data of women with stage IV uterine cancer from the Surveillance, Epidemiology, End Results-Medicare database, researchers herein sought to determine utilization, perioperative outcomes and survival for neoadjuvant chemotherapy (NACT) and cytoreductive surgery (PCS) for stage IV uterine cancer. Among 3,037 identified women, treatment of 1,629 (53.6%) involved primary cytoreductive surgery, 554 (18.2%) received NACT, and 854 (28.1%) were provided no treatment. Observations revealed an increasing use of neoadjuvant chemotherapy for advanced stage uterine cancer. No difference was observed in survival between neoadjuvant chemotherapy and primary cytoreductive surgery. Fewerperioperative medical complications were recorded in correlation with receiving neoadjuvant chemotherapy.